Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
© 2023. The Author(s)..
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Blood cancer journal - 13(2023), 1 vom: 12. Mai, Seite 77 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
117896-08-9 |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 31.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41408-023-00835-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356761584 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356761584 | ||
| 003 | DE-627 | ||
| 005 | 20231226071143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-023-00835-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356761584 | ||
| 035 | |a (NLM)37173322 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sargas, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 31.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Nucleophosmin |2 NLM | |
| 650 | 7 | |a 117896-08-9 |2 NLM | |
| 700 | 1 | |a Ayala, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Larráyoz, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Chillón, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Arboli, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Bilbao, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Prados de la Torre, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Cuadrón, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Veiga, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Boluda, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Bergua, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Algarra, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Tormo, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Sánchez, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Josefina |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Dominguez, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a García, Raimundo |e verfasserin |4 aut | |
| 700 | 1 | |a Amigo, María Luz |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera-Puente, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Sayas, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Lavilla-Rubira, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-López, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Calasanz, María J |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sanz, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Simón, José A |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Casares, María T |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-García, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Barragán, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Montesinos, Pau |e verfasserin |4 aut | |
| 700 | 0 | |a PETHEMA cooperative study group |e verfasserin |4 aut | |
| 700 | 1 | |a Prados de la Torre, Esther |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d 2011 |g 13(2023), 1 vom: 12. Mai, Seite 77 |w (DE-627)NLM219701628 |x 2044-5385 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:12 |g month:05 |g pages:77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41408-023-00835-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 12 |c 05 |h 77 | ||